Trial Profile

A Three-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B and Part C), Multi-Dose, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants with Type 1 Diabetes Mellitus

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY-3938577 (Primary) ; LY-3938577 (Primary) ; Insulin degludec; Insulin degludec
Indications Type 1 diabetes mellitus
Focus Adverse reactions; Pharmacokinetics
Sponsors Eli Lilly and Company

06 May 2025 Planned End Date changed from 1 Aug 2025 to 1 Oct 2025.
06 May 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Oct 2025.
24 Apr 2025 Planned End Date changed from 1 Jul 2025 to 1 Aug 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com